ATE393634T1 - Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels - Google Patents

Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels

Info

Publication number
ATE393634T1
ATE393634T1 AT03014974T AT03014974T ATE393634T1 AT E393634 T1 ATE393634 T1 AT E393634T1 AT 03014974 T AT03014974 T AT 03014974T AT 03014974 T AT03014974 T AT 03014974T AT E393634 T1 ATE393634 T1 AT E393634T1
Authority
AT
Austria
Prior art keywords
inhibiting
cell
bcl
survival rate
cell survival
Prior art date
Application number
AT03014974T
Other languages
English (en)
Inventor
Carl H June
Craig B Thompson
Original Assignee
Us Gov Sec Navy
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/481,739 external-priority patent/US6143291A/en
Application filed by Us Gov Sec Navy, Arch Dev Corp filed Critical Us Gov Sec Navy
Application granted granted Critical
Publication of ATE393634T1 publication Critical patent/ATE393634T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
AT03014974T 1995-05-04 1996-05-02 Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels ATE393634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43551895A 1995-05-04 1995-05-04
US08/481,739 US6143291A (en) 1995-05-04 1995-06-07 Methods for modulating T cell survival by modulating bcl-XL protein level

Publications (1)

Publication Number Publication Date
ATE393634T1 true ATE393634T1 (de) 2008-05-15

Family

ID=27030576

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03014974T ATE393634T1 (de) 1995-05-04 1996-05-02 Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels
AT96913912T ATE244305T1 (de) 1995-05-04 1996-05-02 Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96913912T ATE244305T1 (de) 1995-05-04 1996-05-02 Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels

Country Status (7)

Country Link
EP (1) EP0826043B1 (de)
JP (2) JPH11504814A (de)
AT (2) ATE393634T1 (de)
AU (1) AU5673496A (de)
CA (1) CA2220012C (de)
DE (1) DE69628921T2 (de)
WO (1) WO1996034956A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780891A1 (fr) * 1998-07-10 2000-01-14 Univ Paris Curie Echange de lymphocytes t
JP2002538769A (ja) * 1998-10-30 2002-11-19 ユニバーシティ オブ ネブラスカ−リンカーン アポトーシス遺伝子の異種間移入及びそれにより開発されたトランスジェニック植物
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP5563472B2 (ja) * 2007-11-28 2014-07-30 アイ アール エックス セーラピューティクス， インコーポレイテッド 免疫学的効果を増大させる方法
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
US12419913B2 (en) * 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
KR20220030205A (ko) * 2019-02-08 2022-03-10 디앤에이 투포인토 인크. 면역 세포의 트랜스포존 기반 변형

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods

Also Published As

Publication number Publication date
CA2220012C (en) 2007-10-30
EP0826043B1 (de) 2003-07-02
JPH11504814A (ja) 1999-05-11
DE69628921T2 (de) 2004-04-22
AU5673496A (en) 1996-11-21
EP0826043A1 (de) 1998-03-04
WO1996034956A1 (en) 1996-11-07
ATE244305T1 (de) 2003-07-15
DE69628921D1 (de) 2003-08-07
CA2220012A1 (en) 1996-11-07
JP2008101003A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
DE69918122D1 (de) Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans
DE69020573D1 (de) Verfahren zur wachstumshemmung von stammzellen.
ZA963593B (en) IL-6 activity inhibitor
DE69535448D1 (de) Vorrichtung zur Unterdrückung von stimulierter Brillouin Streuung
BR9611862A (pt) Inibidores de corrosão de neoácido
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
ATE393634T1 (de) Verfahren zur inhibierung der t-zell- ueberlebensrate durch inhibierung des bcl-xl protein-spiegels
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
DE69312498D1 (de) Verfahren zur markierung einer flüssigkeit
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
DE60229639D1 (de) Verwendung von poly-glu, tyr zur neuroprotektiven therapie des zns oder pns
DE68908438D1 (de) Zusammensetzungen und verfahren zur korrosionsinhibierung.
TR199701013T1 (xx) Nitrik oksit synthas'�n�n inhibit�rleri olarak mercapto ve seleno t�revleri.
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
DE69829963D1 (de) Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste
YU18399A (sh) Postupak alkilacije zaštićenih sulfonamida
DE59912547D1 (de) Satellitengestütztes Verteidigungssystem und Verfahren zur satellitengestützten Verteidigung
IL129020A0 (en) Pharmaceutical compositions comprising s-alkylisothiouronium derivatives
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE59813303D1 (de) Disaccharidderivate zur behandlung von hyperglykämien
Matocha PIPELINE INSPECTION AND REHABILITATION--AN OVERVIEW
EP1141022A4 (de) Serinprotease-inhibitor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1384781

Country of ref document: EP

REN Ceased due to non-payment of the annual fee